Skip to content

Ibrutinib

Imbruvica (ibrutinib) is a small molecule pharmaceutical. Ibrutinib was first approved as Imbruvica on 2013-11-13. It is used to treat b-cell chronic lymphocytic leukemia, b-cell lymphoma, mantle-cell lymphoma, and waldenstrom macroglobulinemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and mantle-cell lymphoma. The pharmaceutical is active against tyrosine-protein kinase BTK. In addition, it is known to target cytoplasmic tyrosine-protein kinase BMX, tyrosine-protein kinase Blk, tyrosine-protein kinase Fyn, epidermal growth factor receptor, tyrosine-protein kinase Tec, receptor tyrosine-protein kinase erbB-2, tyrosine-protein kinase ITK/TSK, tyrosine-protein kinase Lyn, tyrosine-protein kinase Yes, proto-oncogene tyrosine-protein kinase Src, tyrosine-protein kinase TXK, tyrosine-protein kinase JAK3, receptor tyrosine-protein kinase erbB-4, tyrosine-protein kinase Lck, and tyrosine-protein kinase HCK. Imbruvica's patents are valid until 2036-03-03 (FDA).
Trade Name Imbruvica
Common Name Ibrutinib
Indication b-cell chronic lymphocytic leukemia, b-cell lymphoma, mantle-cell lymphoma, waldenstrom macroglobulinemia
Drug Class Tyrosine kinase inhibitors: Bruton's (Btk) inhibitors
Ibrutinib
Get full access now